IMMUNOLOGICAL ALTERNATION OF LEUKEMIC CELLS in Vivo AFTER TREATMENT WITH AN ANTITUMOR DRUG

Proceedings of the National Academy of Sciences of the United States of America- United States

doi 10.1073/pnas.66.4.1089

Full Text

Abstract

Available in

Date

Authors

Publisher

Proceedings of the National Academy of Sciences

Related search

Combinatorial Treatment With mTOR Inhibitors and Streptozotocin Leads to Synergistic in Vitro and in Vivo Antitumor Effects in Insulinoma Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2017English

Correction: Granulocyte Maturation After Butyrate Treatment of Leukemic Blasts

Cancer Research
Cancer ResearchOncology
2008English

Induction of Anti-Leukemic Responses by Stimulation of Leukemic CD3+ Cells With Allogeneic Stimulator Cells

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2018English

In Vivo Immunological Toxicity in Mice of Carbon Nanotubes With Impurities

Carbon
Materials ScienceChemistry
2009English

Interaction of Laminin and Fibronectin With Leukemic Cells

Memorias do Instituto Oswaldo Cruz
MedicineMicrobiology
1991English

Arbovirus Evolution in Vivo Is Constrained by Host Alternation

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Chronic Myelogenous Leukemia Cells Contribute to the Stromal Myofibroblasts in Leukemic NOD/SCID MouseIn Vivo

Journal of Oncology
Oncology
2012English

Antitumor Activity of Tetrandrine Citrate in Human Glioma U87 Cells in Vitro and in Vivo

Oncology Reports
MedicineCancer ResearchOncology
2019English

Antitumor Activity of Rhein Lysinate Against Human Glioma U87 Cells in Vitro and in Vivo

Oncology Reports
MedicineCancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy